Biocon Ltd
NSE:BIOCON
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
233.1
391.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Biocon Ltd
Biocon Ltd
Gross Profit
Biocon Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biocon Ltd
NSE:BIOCON
|
Gross Profit
₹99.7B
|
CAGR 3-Years
26%
|
CAGR 5-Years
19%
|
CAGR 10-Years
19%
|
|
|
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
|
Gross Profit
-₹141.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
|
Transgene Biotek Ltd
BSE:526139
|
Gross Profit
₹1.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Z
|
Zenotech Laboratories Ltd
BSE:532039
|
Gross Profit
₹213.7m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Hester Biosciences Ltd
NSE:HESTERBIO
|
Gross Profit
₹2.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Panacea Biotec Ltd
NSE:PANACEABIO
|
Gross Profit
₹3.3B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Biocon Ltd
Glance View
Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,203 full-time employees. The company went IPO on 2004-04-17. The firm is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.
See Also
What is Biocon Ltd's Gross Profit?
Gross Profit
99.7B
INR
Based on the financial report for Sep 30, 2024, Biocon Ltd's Gross Profit amounts to 99.7B INR.
What is Biocon Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
19%
Over the last year, the Gross Profit growth was 10%. The average annual Gross Profit growth rates for Biocon Ltd have been 26% over the past three years , 19% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet
